Corinne Mary Linardic

Corinne Mary Linardic

Associate Professor of Pediatrics

Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3-FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.

Appointments and Affiliations

  • Associate Professor of Pediatrics
  • Associate Professor of Pharmacology and Cancer Biology
  • Member of the Duke Cancer Institute

Contact Information

  • Office Location: LSRC Bldg Rm B361f, Research Drive, Durham, NC 27710
  • Office Phone: (919) 684-3401
  • Email Address: linar001@mc.duke.edu

Education

  • Duke University, 2001
  • Children's Hospital of Philadelphia, 1999
  • Children's Hospital of Philadelphia, 1998
  • American Board of Pediatrics, 1969
  • M.D. Duke University, 1995
  • Ph.D. Duke University, 1993

Awards, Honors, and Distinctions

  • Annual Gordon G. Hammes Faculty Teaching Award. Graduate students in Basic Biomedical Sciences and the Duke University School of Medicine. 2019

Courses Taught

  • PHARM 393: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study

Representative Publications

  • Crose, LES; Etheridge, KT; Chen, C; Belyea, B; Talbot, LJ; Bentley, RC; Linardic, CM, FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 18 no. 14 (2012), pp. 3780-3790 [10.1158/1078-0432.CCR-10-3063] [abs].
  • Ignatius, MS; Chen, E; Elpek, NM; Fuller, AZ; Tenente, IM; Clagg, R; Liu, S; Blackburn, JS; Linardic, CM; Rosenberg, AE; Nielsen, PG; Mempel, TR; Langenau, DM, In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma., Cancer Cell, vol 21 no. 5 (2012), pp. 680-693 [10.1016/j.ccr.2012.03.043] [abs].
  • Belyea, B; Kephart, JG; Blum, J; Kirsch, DG; Linardic, CM, Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting., Sarcoma, vol 2012 (2012) [10.1155/2012/406239] [abs].
  • Belyea, BC; Naini, S; Bentley, RC; Linardic, CM, Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 17 no. 23 (2011), pp. 7324-7336 [10.1158/1078-0432.CCR-11-1004] [abs].
  • Crose, LES; Linardic, CM, Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma., Sarcoma, vol 2011 (2011) [10.1155/2011/756982] [abs].
  • Naini, S; Etheridge, KT; Adam, SJ; Qualman, SJ; Bentley, RC; Counter, CM; Linardic, CM, Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma., Cancer Res, vol 68 no. 23 (2008), pp. 9583-9588 [10.1158/0008-5472.CAN-07-6178] [abs].
  • Linardic, CM, PAX3-FOXO1 fusion gene in rhabdomyosarcoma., Cancer Lett, vol 270 no. 1 (2008), pp. 10-18 [10.1016/j.canlet.2008.03.035] [abs].
  • Linardic, CM; Counter, CM, Genetic modeling of Ras-induced human rhabdomyosarcoma., Methods in Enzymology, vol 438 (2008), pp. 419-427 [10.1016/S0076-6879(07)38028-2] [abs].
  • Linardic, CM; Naini, S; Herndon, JE; Kesserwan, C; Qualman, SJ; Counter, CM, The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence., Cancer Research, vol 67 no. 14 (2007), pp. 6691-6699 [10.1158/0008-5472.CAN-06-3210] [abs].
  • Kendall, SD; Linardic, CM; Adam, SJ; Counter, CM, A network of genetic events sufficient to convert normal human cells to a tumorigenic state., Cancer Research, vol 65 no. 21 (2005), pp. 9824-9828 [10.1158/0008-5472.CAN-05-1543] [abs].
  • Linardic, CM; Downie, DL; Qualman, S; Bentley, RC; Counter, CM, Genetic modeling of human rhabdomyosarcoma., Cancer Research, vol 65 no. 11 (2005), pp. 4490-4495 [10.1158/0008-5472.CAN-04-3194] [abs].